Read as PDF
Lund, Sweden, 17th of October 2017 – Xintela AB (publ)
announces that Keld Søndergaard has resigned from the company’s Board of
Directors, citing personal reasons. Xintela’s larger shareholders, acting as an
informal nomination committee, will consider potential replacement candidates
to propose to the next Annual General Meeting.
Keld Søndergaard was
elected as a new member of the Board at the Annual General Meeting on the 18th
of May 2017. The Board regrets the loss of Keld as a member, but feels certain a
suitable replacement will be found.
Shareholders who have
suggestions for appropriate candidates may contact the Chairman, Greg
Batcheller, via the CEO Evy Lundgren-Åkerlund.
The Xintela Board wishes
Keld Søndergaard all the best in his future endeavors.
Xintela AB (publ)
Evy
Lundgren-Åkerlund, CEO
Tel: 070-329 18 71
Email: evy@xintela.se
Medicon Village
223 81 Lund
www.xintela.se
For investor relations and media questions, please contact:
Mårten Svanberg, Laika Consulting
Tel: 070-362 70 05
Email: marten.svanberg@laika.se
www.laika.se
About Xintela
Xintela develops medical products for regenerative
medicine and cancer based on its proprietary marker technology, XINMARK®. Xintela uses the technology to select and
assure the quality of mesenchymal stem cells for the treatment of cartilage damage and osteoarthritis. In a study on horses,
the company has shown that stem cells are safe to use and that they have a positive effect on the articular
cartilage and the underlying bone after an injury. XINMARK® is also used for the development of an antibody- based
treatment (Antibody Drug Conjugate, ADC) against glioblastoma, the most common
and aggressive form of brain tumors in adults. Positive preclinical results
from cell studies and animal model have shown that the antibody
has a killing effect on glioblastoma cells and thus has confirmed the concept. Xintela is listed on Nasdaq
First North Stockholm since 22 March 2016. Xintela's Certified Adviser at Nasdaq First North is Erik Penser Bank AB,
+46 8-463 80 00.
This information is such information that Xintela AB (publ) is obligated to publish in compliance with the EU market abuse regulation. The information was provided, through the above contact, for publication on the 17th of October 2017, at 09.00 CET.
Below you will find the collected information on Xintela’s press releases, newsletters, diary events, films, media coverage and analyses.
Watch an interview with Professor Stephen Hall, principal investigator in Xintela's phase I/IIa study with XSTEM in knee ostoearthritis. Professor Hall talks about the condition, the study, and what benefit the included patients experienced from the treatment. The interview is moderated by Martin Dominique, chief analyst, Västra Hamnen Corporate Finance.
